Newtyn Management’s Olema Pharmaceuticals OLMA Stock Holding History

Newtyn Management’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-140,000	Closed	-$816K	–	33
2024 Q4	$816K	Hold	140,000	–	–	0.14%	32
2024 Q3	$1.67M	Hold	140,000	–	–	0.26%	35
2024 Q2	$1.51M	Sell	140,000 -10,000	-7%	-$108K	0.28%	33
2024 Q1	$1.7M	Hold	150,000	–	–	0.34%	32
2023 Q4	$2.1M	Hold	150,000	–	–	0.41%	32
2023 Q3	$1.85M	Sell	150,000 -25,000	-14%	-$255K	0.46%	32
2023 Q2	$1.58M	Sell	175,000 -200,000	-53%	-$1.21M	0.37%	34
2023 Q1	$1.3M	Buy	375,000 +15,000	+4%	+$61.2K	0.26%	54
2022 Q4	$882K	Sell	360,000 -40,000	-10%	-$117K	0.18%	56
2022 Q3	$1.1M	Sell	400,000 -100,000	-20%	-$424K	0.24%	49
2022 Q2	$2.04M	Buy	+500,000	New	+$1.59M	0.39%	40

Other funds holding OLMA

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return

Logos Global Management San Francisco, California $1.94B AUM 444.09% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return